Recent news on Cubicin

Cubist Pharmaceuticals to Present at May Conferences  -  Apr 25, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Astellas Pharma: telavancin enters EU battle for MRSA market share  -  May 2, 2007
Pharmaceutical Business Review...(linezolid) first launched in the EU in 2001 (and is already exhibiting resistance, but available orally), Cubist and Novartis’ Cubicin (daptomycin,

2007 BIO International Convention Exhibitor Profiles, A Through D  -  May 3, 2007
Genetic Engineering News (press release),The company's flagship drug, CUBICIN(R) (daptomycin for injection) is a first in class lipopeptide proven clinically successful against both methicillin

Cubist Pharmaceuticals to Present at May Conferences  -  Apr 25, 2007
Business Wire (press release),In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Cubist sees antibiotic Cubicin '07 net rev up 35 pct to 45 pct  -  Apr 18, 2007
ReutersO: Quote, Profile, Research) said it expects 2007 net revenue growth for its antibiotic Cubicin to increase by 35 percent to 45 percent.

Cubist Pharmaceuticals Reports First Quarter 2007 Results: Total ...  -  Apr 18, 2007
Genetic Engineering News (press release),Net sales of CUBICIN(R) (daptomycin for injection) increased 57% from the prior year, from $37.9 million in the first quarter of 2006 to $59.4 million in

Cubist Shares Dive on Sales Results  -  Apr 19, 2007
Forbes,Shares of Cubist Pharmaceuticals Inc. fell Thursday despite improved first-quarter results and a jump in sales for Cubicin, its leading skin-infection

Cubist Pharmaceuticals to Announce First Quarter 2007 Financial ...  -  Apr 6, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Cubist Pharmaceuticals "hold," estimates revised  -  Apr 19, 2007
newratings.comThe upside was driven by higher-than-anticipated Cubicin revenues, the analysts say. Cubist Pharmaceuticals is on track in terms of its label expansion plan

Cubist Swings to 1Q Profit  -  Apr 18, 2007
Forbes,Sales of the company's lead drug, Cubicin, which treats bacterial infections of the skin, increased 57 percent from the prior year.

Cubist Pharmaceuticals "market outperform," target price raised  -  Mar 30, 2007
newratings.comIn a research note published this morning, the analyst mentions that the upward revision in the target price and the estimates reflects the Cubicin sales

GSK meet no resistance for new antibacterial  -  Apr 16, 2007
DrugResearcher.com,In recent months, new antibiotics from the likes of Wyeth (Tygacil; tigecycline) Pfizer (Zyvox; linezolid) and Novartis/Cubist (Cubicin; daptomycin) have

Germs and the City  -  Apr 15, 2007
City Journal,For example, the FDA recently had to decide whether to approve the use of Cubicin against a vicious germ that infects heart valves. Dubbed the “Darth Vader�

Cubist licenses Cubicin to Merck subsidiary  -  Mar 23, 2007
San Antonio Business Journal,Merck plans to develop and commercialize Cubicin in Japan through its wholly-owned subsidiary Banyu Pharmaceuticals Co. Lt.

Cubist Pharmaceuticals Licenses Rights for Development and ...  -  Mar 22, 2007
PipelineReview.com (press release),Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd. With this agreement in Japan,

Cubist Pharma Licenses Rights For Development, Commercialization ...  -  Mar 22, 2007
Trading Markets,As per the deal, Merck will develop and commercialize CUBICIN through its wholly owned subsidiary, Banyu Pharmaceutical Co., Ltd. In exchange for

Merck gets Japan rights to Cubicin  -  Mar 22, 2007
United Press InternationalMerck has further agreed to pay Cubist an undisclosed amount for the supply of Cubicin vials to be sold in Japan. Cubist retains the US marketing rights to

Cubist Inks Licensing Deal With Merck  -  Mar 22, 2007
Forbes,Biotechnology company Cubist Pharmaceuticals Inc. said Thursday it is licensing its antibiotic Cubicin to a Japanese subsidiary of Merck & Co.

Pre-Market Stock News (MAR 22, 2007)  -  Mar 22, 2007
24/7 Wall St.,...(CBST) Cubist Pharma licenses rights for development and commercialization of Cubicin in Japan to Merck. (EBS) Emergent Biosolutions announces the promotion

Cubist Pharmaceuticals to Present at the Leerink Swann & Company ...  -  Feb 28, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Biotech Day in Review: Eisai Buys Morphotek for $325 Million  -  Mar 23, 2007
Seeking Alpha,Cubist (CBST) out-licensed the Japanese rights for its antibiotic Cubicin to Merck (MRK). Cubist will receive $6 million upfront and $39.5 million in

Superbugs driving blockbusters  -  Mar 7, 2007
Monsters and Critics.com,Two drugs currently on the market that are gaining traction against vancomycin include Zyvox and Cubist`s Cubicin, she said.

Cubist Pharmaceuticals to Present at February Investor Conferences  -  Feb 1, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

No Dicey Results for Cubist  -  Jan 29, 2007
Motley FoolCubist received approval from the FDA for a market-expanding new use for its antibiotic treatment Cubicin and grew revenues 61% versus 2005.

From soil in Haiti, hopes for antibiotic  -  Feb 9, 2007
Boston Globe,Its drug, Cubicin, won approval in 2003, and the company sells about $200 million worth of the treatment annually. Two other drug firms have applied for

Novartis pharma chief sees record number of product launches in 2007  -  18 Jan 2007
Forbes,...of the EU's mutual recognition procedures -- and Cubicin for the treatment of skin and soft-tissue infections to be launched in 2007 and 2008, he said.

RPT Novartis pharma chief sees record number of product launches ...  -  18 Jan 2007
Euro2day,...of the EU''s mutual recognition procedures -- and Cubicin for the treatment of skin and soft-tissue infections to be launched in 2007 and 2008, he said.

Cubist Sees Cubicin Sales Up 54 Percent  -  Jan 8, 2007
Forbes,Biotechnology company Cubist Pharmaceuticals Inc. said Monday fourth-quarter US sales of its antibiotic Cubicin jumped 54 percent. Sales of the antibiotic,

Cubist sees Cubicin sales up 54 percent  -  Jan 8, 2007
Hemscott,...(AFX) - Biotechnology company Cubist Pharmaceuticals Inc. said Monday fourth-quarter US sales of its antibiotic Cubicin jumped 54 percent.

Cubist Pharmaceuticals Announces Fourth Quarter 2006 US Net ...  -  Jan 8, 2007
PharmaLive.com (press release),Mike Bonney, President and CEO of Cubist said, "CUBICIN has experienced year-over-year growth of 67% in the US in its third full year as an acute care

Market Report -- In Play (CBST)  -  Jan 8, 2007
MSN Money...$59.68 mln Co announces Q4 US net product revs of $56.2 mln vs. consensus of $59.68 mln for its antibiotic product CUBICIN (daptomycin for injection).

Sector Preview: Biotechnology  -  Jan 9, 2007
Forbes,Cubist Pharmaceuticals (nasdaq: CBST - news - people ) said Monday sales of its lead product Cubicin rose 54 percent during the quarter to $56.2 million.

Sector Preview: Biotechnology  -  Jan 9, 2007
BusinessWeekCubist Pharmaceuticals said Monday sales of its lead product Cubicin rose 54 percent during the quarter to $56.2 million.

Cubist Pharmaceuticals Licenses Rights for Development and ...  -  Dec 4, 2006
PharmaLive.com (press release),AstraZeneca will pay Cubist an undisclosed price for the supply of CUBICIN vials to be sold in the licensed territory. "This agreement is another important

AstraZeneca licenses rights for development and sale of Cubicin in ...  -  Dec 4, 2006
Forbes,As well as China, the agreement also covers certain other countries in Asia, the Middle East and Africa not already covered by existing Cubicin

AstraZeneca licenses rights to Cubist's Cubicin in China  -  Dec 5, 2006
Pharma Times (subscription),Under the terms of the deal, AstraZeneca will pay Cubist $10.25 million cash upfront plus an undisclosed price for the supply of Cubicin vials.

Cubist Pharmaceuticals licenses antibiotic Cubicin in China to ...  -  Dec 4, 2006
MarketWatchCubist Pharmaceuticals Inc. (CBST) licensed development and commercialization rights for its Cubicin antibiotic in China and other countries in Asia,

Inside FDA, a Battle Over Drug To Treat 'Darth Vader' Bacteria  -  Nov 30, 2006
Wall Street Journal (subscription),FDA officials battled earlier this year when deciding whether to approve the antibiotic Cubicin for heart-valve infections. Staff reviewers urged their boss

Cubist Finds an Asian Partner  -  Dec 5, 2006
MSNBCIn return for getting the rights to market Cubicin in China and certain other Asian countries, as well as places like the Middle East and Africa,

Cubist Pharmaceuticals to Present at December Investor Conferences  -  Nov 30, 2006
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Cubist inks licensing deal with AstraZeneca  -  Dec 4, 2006
Bizjournals.com,...based company (Nasdaq: CBST) generated $113.5 million in sales in 2005 from Cubicin, only a year after the drug went on the market.

Cubist inks AstraZeneca licensing deal  -  Dec 4, 2006
BusinessWeekDrug developer Cubist Pharmaceuticals Inc. on Monday said it signed a $10.3 million licensing agreement with AstraZeneca PLC to market Cubicin antibiotic in

AstraZeneca to sell Cubist antibiotic in China  -  Dec 4, 2006
ReutersThe agreement also includes certain other countries in Asia, the Middle East and Africa not covered by existing Cubicin agreements, but not Japan,

Piper Jaffray downgrades Cubist Pharma (CBST) to Market Perform  -  Dec 8, 2006
StreetInsider.com (subscription),Piper Jaffray downgrades Cubist Pharma (Nasdaq: CBST) from Outperform to Market Perform and lowers their price target to $23, saying they expect Q4 Cubicin

Duke in the News: Dec. 1, 2006  -  Dec 1, 2006
Duke University,Corey calls resistant staph the "Darth Vader" of bacteria and says doctors "urgently need a new option," which the antibiotic Cubicin could provide.

Cubist deploys Pillar Data’s Axiom storage system  -  Nov 30, 2006
CTR,In the US, Cubist markets its CUBICIN daptomycin for injection, the first antibiotic in a new class of antiinfectives called lipopeptides.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional